Table 2.
Response to Conventional TACE and CT-Guided 125I Brachytherapy
| Patient No. | Location | Total Sessions of TACE | Last Conventional TACE | CT-Guided 125I Brachytherapy | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Size (cm) | Tumour Shape on CT | Lipiodol Accumulation on Follow-Up CT After cTACE, % | Size (cm) | Response by mRECIST | Pre-RT AFP | Post-RT AFP | No. of 125I Seeds | Complications | |||
| 1 | S8 | 2 | 5.4 | Nodular | 30% | 4.5 | PR | 239.64 | 65.48 | 50 | None |
| 2 | S4 | 5 | 5.5 | Nodular | 50% | 5.1 | CR | 351.97 | 3.8 | 20 | None |
| 3 | S5–6 | 3 | 5.9 | Nodular | 40% | 5.7 | CR | 3.5 | 5.2 | 80 | None |
| 4 | S7 | 6 | 6.8 | Nodular | 10% | 7.0 | SD | 687.1 | 256.5 | 80 | None |
| 5 | S5–8 | 5 | 8.2 | Nodular | 40% | 8.0 | PR | 3526 | 1520 | 54 | None |
| 6 | S4 | 3 | 2.8 | MultiNodular | 0% | 2.6 | CR | 6.4 | 4.3 | 25 | None |
| S5 | 1.5 | <5% | 1.5 | CR | 15 | ||||||
| 7 | S8 | 4 | 3.9 | Nodular | 30–40% | 3.1 | PR | 228.2 | 29.8 | 40 | Perihepatic haemorrhage |
| 8 | S5–8 | 2 | 9.5 | Nodular | 30–40% | 9.0 | PR | 1210 | 6.2 | 60 | None |
| 9 | S7 | 8 | 2.8 | Nodular | 20–30% | 2.5 | CR | 2276 | 9.2 | 40 | Pneumothorax |
| 10 | S3 | 6 | 1.8 | MultiNodular | 10% | 1.8 | CR | 3.7 | 2.8 | 12 | None |
| S4 | 2.0 | <5% | 1.9 | CR | 18 | ||||||
| 11 | S3 | 4 | 4.4 | Nodular | 40% | 3.5 | CR | 3366 | 919.9 | 50 | None |
| 12 | S8 | 4 | 4.0 | Nodular | 5–10% | 3.7 | PR | 15.7 | 11.1 | 50 | Pneumothorax |
| 13 | S3 | 3 | 1.6 | Nodular | 0% | 1.6 | PR | 11.2 | 8.5 | 20 | None |
| 14 | S4 | 5 | 11.9 | Infiltrating | 20–30% | 11.6 | SD | 5.8 | 31.5 | 90 | None |
| 15 | S7 | 2 | 3.3 | Nodular | 5% | 3.2 | CR | 3411 | 1476 | 45 | None |
| 16 | S6 | 3 | 1.5 | Nodular | 30–40% | 1.8 | CR | 6.2 | 3.2 | 20 | None |
| 17 | S2 | 2 | 1.9 | Nodular | 5–10% | 2.0 | CR | 4.2 | 6 | 22 | None |
| 18 | S8 | 2 | 4.6 | Nodular | 40% | 4.2 | PR | 26.2 | 6.6 | 60 | Pneumothorax |
| 19 | S6 | 6 | 1.8 | Nodular | 30–40% | 1.7 | CR | 2297 | 1822 | 20 | None |